Breaking News

Tweet TWEET

The European Organisation for Rare Diseases (EURORDIS) Awards Celgene Corporation for Excellence in Medical Innovation in Rare

  The European Organisation for Rare Diseases (EURORDIS) Awards Celgene
  Corporation for Excellence in Medical Innovation in Rare Diseases

Business Wire

BOUDRY, Switzerland -- February 27, 2013

EURORDIS (The European Organisation for Rare Diseases) announced today that
Celgene Corporation (NASDAQ:CELG) has been awarded the prestigious EURORDIS
Company Award for excellence in the field of rare diseases. The award,
presented just in advance of Rare Diseases Day, February 28, recognises
Celgene’s established track record in the area of orphan diseases, with
multiple orphan designations and approved disease-altering therapies
addressing patient needs and a robust pipeline of innovative compounds under
development. The award also acknowledges Celgene’s efforts to engage in
quality dialogue and partnership with EURORDIS and patient groups in relevant
disease areas.

The EURORDIS Awards recognise outstanding patients' advocacy groups,
volunteers, scientists, companies, media, and policy makers who have
contributed to reducing the impact of rare diseases on people's lives. The
winners of the awards are selected from more than 100 nominations received
from EURORDIS members including rare disease patient advocacy groups across
Europe, volunteers and staff.

With 17 orphan drug designations* and four approved orphan drug indications
granted by the European Medicines Agency (EMA), Celgene holds a leading
position among companies developing therapies for rare diseases^1. The Celgene
pipeline currently includes active clinical trial programs in 45 rare
conditions, with Celgene investing 31% of its annual revenues into ongoing
research and development efforts. As part of these efforts, there is a clear
commitment from the company to continue extensive research in the area of rare
diseases, which is the foundation on which the company was built.

“We are honored to receive the EURORDIS Company Award for our work in rare
diseases, which is a testament to the strong partnerships we have throughout
Europe with the people focused on treatment options for some of the most
difficult-to-study and difficult-to-treat conditions,” said Stefano Portolano,
M.D., Vice President, Hematology Europe at Celgene, who accepted the award on
behalf of Celgene. “In the nearly 13 years since the Orphan Drug Regulation
was enacted, there has been growing recognition of the need for treatments for
rare diseases that help patients live longer and higher quality lives. Celgene
is proud to be recognized for its contributions in this area, along with the
important work by groups like EURORDIS.”

A recent demonstration of Celgene’s ongoing efforts to drive clinical advances
and provide new therapeutic options for patients with rare diseases was the
announcement on 8 February 2013 of the U.S. Food and Drug Administration (FDA)
approval of pomalidomide for patients with multiple myeloma, who received at
least two prior therapies including lenalidomide and bortezomib and have
demonstrated disease progression on or within 60 days of completion of the
last therapy. Pomalidomide is currently under review by the European
regulatory authority, the European Medicines Authority (EMA).

Yann Le Cam, Chief Executive Officer, EURORDIS, commented; “We are honoured to
acknowledge the commitment and achievements of this year’s recipients of the
EURORDIS Awards on the occasion of Rare Disease Day 2013. Each of this year’s
ten awardees contributes in their own unique way toward fostering the goals of
cooperation embodied in this year’s Rare Disease Day slogan: ‘Rare Disorders
without Borders’. We are proud that the rare disease community is becoming a
model for multi-stakeholder partnership and international collaboration as
well as for solidarity and unity throughout Europe.”

Orphan diseases are rare and often debilitating conditions, defined in the
European Union as affecting no more than five per 10,000 people. There are
between 5,000 and 8,000 different rare diseases affecting an estimated 29
million people in the EU.

* Special regulatory status, granted to a product developed to treat rare
diseases

                                    -ends-

NOTES TO EDITORS

About Celgene

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel,
Switzerland, is a wholly owned subsidiary and international headquarters of
Celgene Corporation.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global pharmaceutical company engaged primarily in the discovery, development
and commercialization of innovative therapies for the treatment of cancer and
inflammatory diseases through gene and protein regulation. For more
information, please visit the Company's website at www.celgene.com.

Celgene has been operating in Europe since 2006 and is currently present in 22
EU countries. By utilizing the latest advances in molecular and cellular
research to develop novel therapies that target the mechanisms of disease at
their source, Celgene is driving clinical advances in debilitating diseases
for patients with the biggest unmet medical needs. Current Celgene portfolio
covers a wide range of rare conditions including: acute myeloid leukaemia,
chronic lymphocytic leukaemia, cutaneous T-cell lymphoma, multiple myeloma,
myelodysplastic syndromes and primary myelofibrosis, Bechet’s disease to name
but a few.

About the EURORDIS Awards 2013

EURORDIS is a leading International Non-Governmental Organisation (INGO) and
is recognised as the largest European patient organisation in the field of
rare diseases. The EURORDIS Awards recognise outstanding patients' advocacy
groups, volunteers, scientists, companies, media, and policy makers who have
contributed - directly or indirectly - to reducing the impact of rare diseases
on people's lives.

References:

1. Community Register of Orphan Medicinal Products for Human Use; accessed 22
October 2012

Contact:

Celgene
Stacey Minton
+41 32 729 62 36
sminton@celgene.com
 
Press spacebar to pause and continue. Press esc to stop.